Medical Health Cluster

Farmacos Covid19

ECDC Gives Guidance on Prevention and Treatment of Monkeypox

In a new risk-assessment document, the European Centre for Disease Prevention and Control (ECDC) summarizes what we currently know about monkeypox and recommends that European countries focus on the identification and management of the disease as well as contract tracing and prompt reporting of new cases of the virus. Recent […]

Read More

Psilocybin Effective Up to 12 Weeks in Severe Depression

NEW ORLEANS – A single dose of a synthetic formulation of psilocybin provides rapid improvement in treatment-resistant depression, with benefits sustained for up to 12 weeks, according to results from the largest randomized controlled study of psilocybin to date. Dr Guy Goodwin “This is easily the largest study of a psychedelic drug employing […]

Read More

COVID-19 en México: Especialista alerta que 12 estados presentan repuntes significativos

México está cerrando su ciclo epidémico y transitando al estado endémico de la pandemia de COVID-19, aseguró a finales de abril de este año el subsecretario de Salud, Hugo López-Gatell. Sin embargo, ya son 12 entidades federativas que presentan repuntes significativos, de acuerdo con Arturo Erdély, actuario y doctor en Ciencias matemáticas por la UNAM. Arturo Erdély, quien se ha dedicado al análisis estadístico de la […]

Read More

Moderna says new trial results show that a revised vaccine works better against Omicron.

A significantly stronger immune response against Omicron is seen, but it remains unclear how an updated vaccine will fare against future versions of the virus. Moderna released preliminary results on Wednesday on an updated coronavirus vaccine that targets the Omicron variant, calling it “our lead candidate” to serve as a U.S. booster […]

Read More

National Academies: US Nursing Home System Needs Fundamental Overhaul

The COVID-19 crisis publicly exposed systemic problems within the US nursing home system, where about 40% of deaths from SARS-CoV-2 infection occurred during the pandemic’s first year. Now, a major report provides a blueprint for overhauling what the authors concluded is an “ineffective, inefficient, fragmented, and unsustainable” approach to long-term and postacute care. […]

Read More

Buenos resultados de seguridad e inmunidad de la dosis de recuerdo con la variante Beta de Sanofi

En un artículo aun en preprint, la farmacéutica Sanofi presenta los resultados de su vacuna adyuvada con AS03 frente al SARS-CoV-2, que incluye la variante beta administrada como dosis de recuerdo en aquellos que recibieron un priming, de 3 a 7 meses antes, con dos dosis de vacuna Comirnaty. Patrocinado por el […]

Read More

Emergence and Evolution of H5N1 Bird Flu

Emergence and Evolution of H5N1 Bird Flu (Text Version) [illustration of different bird types] 1996-1997 H5N1 bird flu viruses first detected In 1996, highly pathogenic avian influenza H5N1 virus is first identified in domestic waterfowl in Southern China. The virus is named A/goose/Guangdong/1/1996. In 1997, H5N1 poultry outbreaks happen in […]

Read More

Estado de la vacunación pediátrica contra COVID-19: actualización de Iberoamérica y Estados Unidos

España La población de 0 a 19 años de edad suma un total de 9’219.654 personas, lo que representa 19,4% de la población total. La población del grupo de edad de 5 a 11 años es de 3’355.137, es decir, 7% de la población total, según el Instituto Nacional de Estadística (INE) de España. […]

Read More

Fidaxomicin Favored Over Vancomycin in Real-World C diff Study

Fidaxomicin (Fificid) emerged favorable to vancomycin for the treatment of both initial and recurrent Clostridioides difficile infections in a Medicare population, according to a new retrospective study. Although fidaxomicin was about 14% more effective than vancomycin in treating the initial infection, a larger difference of 30% was found among people with recurrent C difficile infections. Lead investigator […]

Read More